Comparison of regulatory criteria in Bioequivalence in the US, EU, Japan and South Korea

Abstract

The global market for generic drugs is experiencing unprecedented growth, driven by the rising demand for cost-effective therapeutic alternatives and the increasing burden of healthcare costs. In this context, bioequivalence (BE) studies are pivotal in ensuring that generic drugs deliver therapeutic effects comparable to those of their reference drugs. However, regulatory standards for BE study vary significantly across regions, influencing the development, approval processes, and global market entry of generic drugs. Among the key challenges in BE study, highly variable drugs (HVDs) and narrow therapeutic index drugs (NTIDs) stand out due to their unique pharmacokinetic and pharmacodynamic profiles, necessitating tailored regulatory approaches. This study aims to address these challenges by conducting a comparative analysis of BE regulatory standards in the United States, Europe, Japan, and South Korea, focusing on the differences in approaches to HVDs and NTIDs. To achieve this, a multi-faceted methodology was adopted, encompassing an extensive review of BE guidelines from regulatory authorities (FDA, EMA, PMDA, MFDS) and a case study analysis using Telmisartan (HVD) and Tacrolimus (NTID) as representative examples. The study analyzed critical pharmacokinetic parameters, including 90% confidence intervals (CI) and intra-subject coefficient of variation (ISCV), to highlight regional regulatory differences. The findings reveal notable disparities in regulatory standards. For HVDs, the FDA demonstrates greater flexibility through the application of Reference-Scaled Average Bioequivalence (RSABE), which allows expanded CI ranges based on ISCV thresholds. The EMA adopts a moderately flexible approach, requiring strong justification for reference-scaling. PMDA in Japan offers limited explicit guidance, relying on case-by-case flexibility, while MFDS in South Korea closely aligns with FDA standards but imposes additional requirements, such as domestic BE study. For NTIDs, stricter CI limits are consistently applied across regions, with the United States and South Korea adopting the most rigorous standards, reflecting the critical safety considerations for these drugs. These regulatory differences have significant implications for generic drug development. While the flexibility for HVDs facilitates their approval under specific conditions, the stringent requirements for NTIDs pose challenges in achieving BE. Furthermore, the lack of harmonization among regions creates additional hurdles for pharmaceutical companies seeking simultaneous global market entry. For instance, regulatory variability necessitates region-specific BE studies, increasing costs and development timelines. This study underscores the necessity of region-specific regulatory strategies for HVDs and NTIDs, highlighting the need for tailored approaches to address their unique challenges while ensuring patient safety. Additionally, the findings emphasize the importance of international regulatory harmonization to streamline the development and approval processes for generic drugs. Future research should expand the scope by incorporating additional drug cases and exploring pathways for greater alignment in regulatory standards. Such efforts will not only enhance the feasibility of generic drug development but also improve global access to affordable and effective medications.;제네릭 의약품 시장은 빠르게 성장하며 환자들에게 경제적인 치료 옵션을 제공하고 있습니다. 제네릭 의약품 개발에서 생물학적 동등성시험은 오리지널 의약품과 동일한 치료 효과를 보장하기 위한 필수적인 절차입니다. 그러나 생물학적 동등성시험의 규제 기준은 국가별로 상이하여, 글로벌 제네릭 의약품 개발 및 시장 진출에 영향을 미칩니다. 본 연구는 미국, 유럽, 일본, 한국의 생물학적 동등성시험 규제 기준을 비교하고, 고변동성 약물(HVDs)과 좁은 치료영역 약물(NTIDs)의 규제 접근법과 유연성 차이를 분석하였습니다. 이를 위해 각국 규제기관의 가이드라인과 문헌을 검토하고, Telmisartan(HVDs)과 Tacrolimus(NTIDs)을 사례로 실제 데이터를 비교 분석하였습니다. Telmisartan은 Cmax 변동폭이 94.23%에서 127.01%로 대상자 내 변동계수(ISCV)가 45.90%에 이르는 높은 변동성을 보였으며, Tacrolimus는 AUC 범위가 96.66%에서 102.73%로 ISCV가 11%로 안정적인 결과를 보였습니다. 이러한 분석은 HVDs와 NTIDs의 약동학적 특성과 규제 기준의 차이를 보여줍니다. 본 연구는 HVDs와 NTIDs의 특성을 고려한 맞춤형 규제 접근의 중요성을 강조하며, 지역별 규제 차이가 제네릭 의약품 개발 및 시장 진출에 미치는 영향을 조명하였습니다. 또한, 글로벌 시장에서의 제네릭 의약품 접근성을 높이기 위해 규제 조화의 필요성과 이를 위한 미래 연구 방향을 제안하였습니다.